An analyst wrote that with selonsertib's failures in fourth- and now third-stage fibrosis, the drug will have no place in NASH treatment. Gilead has entered partnerships focused on other compounds for the fatty liver disease.
The French company, developing a drug to treat nonalcoholic steatohepatitis, or NASH, announced the pricing of its shares at $20.32 apiece.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company, one of several developing drugs for the growing fatty liver disease, said in an SEC filing that it would sell its shares at $26.33 apiece.
Shares of the New York-based company jumped nearly 20 percent Tuesday on news that the REGENERATE study of obeticholic acid showed strong improvement in NASH-related liver fibrosis.
The company joins a growing wave of firms developing drugs for the disease, which has no approved treatments. It expects to enter two drugs into the clinic next year.
The companies will run clinical trials combining Novartis' tropifexor with any one of several Pfizer drugs under development for the disease, which lacks approved treatments.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The new company is headquartered in San Francisco, with R&D in Israel and has launched a Phase I study of BIO89-100, formerly TEV-47948.
The company secured $60 million in a Series A round from Third Rock and Takeda, plus a partnership with Takeda.
From clinical trial saturation to a suspiciously strong placebo effect: Here are some of the major challenges facing biopharma companies in pursuit of the first FDA-approved therapy for non-alcoholic steatohepatitis (NASH).
Cookies and milk or cookies and colostrum? Immuron is targeting inflammatory bacteria in the gut with an engineered colostrum formulation, designed to prevent the liver damage that leads to NASH.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.